ObsEva SA (NASDAQ:OBSV) – Equities researchers at Jefferies Financial Group issued their FY2025 earnings per share (EPS) estimates for shares of ObsEva in a research report issued to clients and investors on Tuesday, January 12th. Jefferies Financial Group analyst B. Amin forecasts that the company will post earnings of ($0.71) per share for the year.
Several other brokerages also recently commented on OBSV. Zacks Investment Research raised shares of ObsEva from a “sell” rating to a “hold” rating in a research note on Tuesday. JPMorgan Chase & Co. downgraded ObsEva from a “neutral” rating to an “underweight” rating in a report on Monday, November 9th. SVB Leerink boosted their price objective on ObsEva from $4.00 to $5.00 and gave the stock an “outperform” rating in a report on Tuesday. HC Wainwright reduced their target price on shares of ObsEva from $23.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, January 4th. Finally, Wedbush reissued a “buy” rating and set a $28.00 price target on shares of ObsEva in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. ObsEva has an average rating of “Hold” and an average target price of $10.21.
ObsEva (NASDAQ:OBSV) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.15).
A number of institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in shares of ObsEva during the third quarter worth $27,000. GSA Capital Partners LLP acquired a new stake in shares of ObsEva during the 3rd quarter valued at $38,000. Wedbush Securities Inc. grew its position in ObsEva by 19.5% during the 3rd quarter. Wedbush Securities Inc. now owns 179,037 shares of the company’s stock worth $444,000 after acquiring an additional 29,241 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in ObsEva in the 3rd quarter worth about $114,000. Finally, State Street Corp bought a new position in ObsEva in the third quarter valued at about $124,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.
ObsEva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
Further Reading: How is a Moving Average Calculated?
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.